JP2016512561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512561A5 JP2016512561A5 JP2016501961A JP2016501961A JP2016512561A5 JP 2016512561 A5 JP2016512561 A5 JP 2016512561A5 JP 2016501961 A JP2016501961 A JP 2016501961A JP 2016501961 A JP2016501961 A JP 2016501961A JP 2016512561 A5 JP2016512561 A5 JP 2016512561A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- solvate
- acceptable salt
- naltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 186
- 150000003839 salts Chemical class 0.000 claims description 78
- 239000011780 sodium chloride Substances 0.000 claims description 78
- 239000012453 solvate Substances 0.000 claims description 75
- 208000002193 Pain Diseases 0.000 claims description 62
- 229960003086 Naltrexone Drugs 0.000 claims description 51
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 49
- 102100012087 TLR4 Human genes 0.000 claims description 37
- 101700022711 TLR4 Proteins 0.000 claims description 37
- 230000003042 antagnostic Effects 0.000 claims description 37
- 239000005557 antagonist Substances 0.000 claims description 37
- 230000003364 opioid Effects 0.000 claims description 37
- 241000124008 Mammalia Species 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 29
- 239000000651 prodrug Substances 0.000 claims description 21
- 229940002612 prodrugs Drugs 0.000 claims description 21
- 239000002552 dosage form Substances 0.000 claims description 20
- SXLHPBDGZHWKSX-UHFFFAOYSA-N 1-(5-amino-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(N)=CC=C1O SXLHPBDGZHWKSX-UHFFFAOYSA-N 0.000 claims description 16
- -1 norbinal tolfimine Chemical compound 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- YUSWMAULDXZHPY-UHFFFAOYSA-N Amentoflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 YUSWMAULDXZHPY-UHFFFAOYSA-N 0.000 claims description 12
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 10
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 9
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 9
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 9
- 229960004127 Naloxone Drugs 0.000 claims description 9
- 208000004296 Neuralgia Diseases 0.000 claims description 9
- 229960005297 nalmefene Drugs 0.000 claims description 9
- 206010053552 Allodynia Diseases 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- 206010027599 Migraine Diseases 0.000 claims description 7
- 208000008085 Migraine Disorders Diseases 0.000 claims description 7
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims description 7
- JVLBPIPGETUEET-WIXLDOGYSA-O (3R,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims description 6
- ZHVWWEYETMPAMX-PCWWUVHHSA-N Naltriben Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3OC=25)O)CC1)O)CC1CC1 ZHVWWEYETMPAMX-PCWWUVHHSA-N 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 230000002496 gastric Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007937 lozenge Substances 0.000 claims description 6
- 229960002921 methylnaltrexone Drugs 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 230000002459 sustained Effects 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 230000000699 topical Effects 0.000 claims description 6
- 206010036376 Post herpetic neuralgia Diseases 0.000 claims description 5
- 230000000875 corresponding Effects 0.000 claims description 5
- 230000002195 synergetic Effects 0.000 claims description 5
- 239000011885 synergistic combination Substances 0.000 claims description 5
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims description 4
- 206010012680 Diabetic neuropathy Diseases 0.000 claims description 4
- RYIDHLJADOKWFM-MAODMQOUSA-N Samidorphan Chemical compound N1([C@@H]2CC3=CC=C(C(=C3[C@@]3([C@]2(CCC(=O)C3)O)CC1)O)C(=O)N)CC1CC1 RYIDHLJADOKWFM-MAODMQOUSA-N 0.000 claims description 4
- 229950006776 Samidorphan Drugs 0.000 claims description 4
- DKJCUVXSBOMWAV-PCWWUVHHSA-N Naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 8
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 8
- 229960002896 clonidine Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- 229960001680 ibuprofen Drugs 0.000 description 7
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- AYXYPKUFHZROOJ-ZETCQYMHSA-N (3S)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 229960002870 gabapentin Drugs 0.000 description 4
- 229960001233 pregabalin Drugs 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6β-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 description 2
- 206010058019 Cancer pain Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010019233 Headache Diseases 0.000 description 2
- IWBJJCOKGLUQIZ-HQKKAZOISA-N Hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000000399 Procedural Pain Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 230000002917 arthritic Effects 0.000 description 2
- CUHVIMMYOGQXCV-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CNC=N1 CUHVIMMYOGQXCV-NSHDSACASA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- UZHSEJADLWPNLE-PIKADFDJSA-N (4S,4aR,7aS,12bR)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@H]1O2)CC[C@]3(O)[C@@H]4CC5=CC=C(O)C2=C5[C@]13CCN4CC=C UZHSEJADLWPNLE-PIKADFDJSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N Apraclonidine Chemical group ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229960005084 CALCITRIOL Drugs 0.000 description 1
- 229960001209 CLONIXIN Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N Clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001894 DETOMIDINE Drugs 0.000 description 1
- JXMXDKHEZLKQPB-UHFFFAOYSA-N Detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
- 229960002783 Dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N Dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N Droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960004369 Flufenamic Acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 206010061979 Genital pain Diseases 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 229960002048 Guanfacine Drugs 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N Lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N Lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- KDPNLRQZHDJRFU-UHFFFAOYSA-N Romifidine Chemical compound FC1=CC=CC(Br)=C1NC1=NCCN1 KDPNLRQZHDJRFU-UHFFFAOYSA-N 0.000 description 1
- 241000293861 Scrophularia nodosa Species 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N Tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960000488 Tizanidine Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N Tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960005089 romifidine Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
Description
äžå®æœåœ¢æ
ã§ã¯ãæ¬é瀺ã¯ãå»è¬çµæç©ããç¥çµé害æ§çŒçãèéšçãæ
¢æ§çŒçãç³å°¿ç
æ§ç¥çµé害æ§çŒçãäžåç¥çµçãå¹»è¢çãè€åæ§å±æçŒççå矀ã®çã¿ã垯ç¶ç±ç¹åŸçãçŒç±çãç¹çºæ§çŒçãççæ§çŒçãçæ§çŒçãè¡åŸçŒçãç·ç¶ççãé çãçé çãã¢ããã£ãã¢çŒçãå€é°éšçãé質æ§èè±ççŒçãéææ§è
žçå矀ïŒïŒ©ïŒ¢ïŒ³ïŒãé¢ç¯ççŒçãåã³è
±çãæ²»çãããäºé²ãããåã³ãããããå埩ãããããã«äœ¿çšããããçã¿ã®æ²»çã®ããã®æ¹æ³ãæäŸãããå¥ã®å®æœåœ¢æ
ã§ã¯ãæ¬é瀺ã¯ãå»è¬çµæç©ãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãæ²»çãããäºé²ãããåã³ããããå埩ãããããã«äœ¿çšããããæ¹æ³ãæäŸããã
[æ¬çºæ1001]
çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1002]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1003]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããã®ãããã©ãã°ããŸãã¯ãã®ããããã®ä»»æã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1004]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããããã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1003ã®é åãå«ãçµæç©ã
[æ¬çºæ1005]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1003ã®é åãå«ãçµæç©ã
[æ¬çºæ1006]
åèšçŽæ¥äœååα2ã¢ãã¬ããªã³äœåè¬ã¯ãã¢ãã©ã¯ãããžã³ãããªã¢ããžã³ãã¯ãããžã³ãããããžã³ããã¯ã¹ã¡ããããžã³ãã°ã¢ããã³ãºãã°ã¢ã³ãã¡ã·ã³ãããã§ãã·ãžã³ãã¡ããããžã³ããããã£ãžã³ããã¶ããžã³ãããããžã³ããã·ã©ãžã³ãåã³ãã¡ãã«ããžã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1007]
åèšçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ã¯ãã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1008]
åèšçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ã¯ãæç¶æŸåºæ§è£œå€äžã®ã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1009]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ã¯ãæ²»çæå¹éã®ã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1010]
ãã«ãã¬ããœã³ãšã¯ãããžã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã90ïŒ1ã22ïŒ5ïŒ1éééšã®ãªãŒããŒã®çžä¹çãªçµã¿åããç¯å²ã«å¯Ÿå¿ãããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1009ã®çµæç©ã
[æ¬çºæ1011]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ã1æ¥åœããçŽ0ïŒ00018ïœïœïŒïœïœã0ïŒ0086ïœïœïŒïœïœã§ãããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1012]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããã¯ãããžã³ã®ããçšéç¯å²ã¯ã0ïŒ0125ïœïœã0ïŒ6ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1013]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããã¯ãããžã³ã®ããçšéç¯å²ã¯ã0ïŒ0125ïœïœã0ïŒ3ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1014]
1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1015]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1016]
åèšçµã¿åããã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1017]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1018]
èéšçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1019]
ç¥çµé害æ§çŒçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1020]
çé çã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1021]
äžåç¥çµçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1022]
å€é°éšçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1023]
éææ§è žçå矀ã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1024]
垯ç¶ç±ç¹åŸç¥çµçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1025]
ç³å°¿ç æ§ç¥çµé害ã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1026]
ã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1027]
çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1028]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1027ã®é åãå«ãçµæç©ã
[æ¬çºæ1029]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1027ã®é åãå«ãçµæç©ã
[æ¬çºæ1030]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1029ã®é åãå«ãçµæç©ã
[æ¬çºæ1031]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1029ã®é åãå«ãçµæç©ã
[æ¬çºæ1032]
ã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã第2ã®ååç©ã§ãããæ¬çºæ1027ã®é åãå«ãçµæç©ã
[æ¬çºæ1033]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã¯ãæ²»çæå¹éã§ãããæ¬çºæ1027ã®çµæç©ã
[æ¬çºæ1034]
ãã«ãã¬ããœã³ãšã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã3ïŒ200éééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1027ã®çµæç©ã
[æ¬çºæ1035]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ã1æ¥åœããçŽ5ïœïœïŒïœïœã57ïœïœïŒïœïœã§ãããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1036]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã®ããçšéç¯å²ã¯ã325ïœïœã4000ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1037]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã®ããçšéç¯å²ã¯ã325ïœïœã4000ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1038]
1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1039]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1040]
ãã«ãã¬ããœã³åã³ã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1041]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1027ã®çµæç©ã
[æ¬çºæ1042]
ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçã䟵害å容æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãççãå€åœ¢æ§é¢ç¯çãé¢ç¯ãªãŠããã也ç¬æ§é¢ç¯çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããæ¹æ³ã§ãã£ãŠãæ¬çºæ1034ã®æ²»çæå¹éã®çµã¿åãããã該åºä¹³åç©ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1043]
çžä¹çæ¯çã®ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1044]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1045]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1046]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1045ã®é åãå«ãçµæç©ã
[æ¬çºæ1047]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1045ã®é åãå«ãçµæç©ã
[æ¬çºæ1048]
åèšã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ã¯ãã¢ã¹ããªã³ããžãã«ããµã«ããµã«ãµã¬ãŒããã€ããããã§ã³ããã¯ã¹ã€ããããã§ã³ãããããã»ã³ããã§ããããã§ã³ãã±ããããã§ã³ããã¯ã¹ã±ããããã§ã³ããã«ã«ããããã§ã³ããªããµãããžã³ããããœãããã§ã³ãã€ã³ãã¡ã¿ã·ã³ããã«ã¡ãã³ãã¹ãªã³ãã¯ããšããã©ã¯ãã±ããã©ã¯ããžã¯ããã§ãã¯ïŒïœïœïœïœïœïœ ïœïœïœïŒãããã¡ãã³ããããã·ã«ã ãã¡ããã·ã«ã ããããã·ã«ã ããããã·ã«ã ããã«ããã·ã«ã ãã€ãœãã·ã«ã ãã¡ãã§ãã é žãã¡ã¯ããã§ãã é žããã«ãã§ãã é žããã«ãã§ãã é žãã»ã¬ã³ãã·ããããã§ã³ãã·ãããã«ãã³ãã·ãããã¬ã³ãã·ããã«ãã©ã³ãã·ãããšããªã³ãã·ãããã£ãã³ãã·ããã¹ã«ãã³ã¢ããªãããã¡ã¹ãªãããªã³ãã§ãã³ããªãžã³ãã¯ãããã·ã³é žãããã«ãã©ãªã³ããŽãããã°ãµãã«ã«ã·ããªãªãŒã«ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1049]
åèšã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ã¯ãã€ããããã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1050]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ã¯ãæ²»çæå¹éã®ã€ããããã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1043ã®çµæç©ã
[æ¬çºæ1051]
ãã«ãã¬ããœã³ãšã€ããããã§ã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã1ïŒ90éééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1052]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããã€ããããã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ã1æ¥åœããçŽ3ïœïœïŒïœïœã35ïœïœïŒïœïœã§ãããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1053]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããã€ããããã§ã³ã®ããçšéç¯å²ã¯ã200ïœïœã2400ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1054]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããã€ããããã§ã³ã®ããçšéç¯å²ã¯ã200ïœïœã2400ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1055]
1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1056]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1057]
åèšçµã¿åããã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1058]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1043ã®çµæç©ã
[æ¬çºæ1059]
ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçã䟵害å容æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããæ¹æ³ã§ãã£ãŠãæ¬çºæ1050ã®æ²»çæå¹éã®çµã¿åãããã該åºä¹³åç©ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1060]
çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒÎ±â2âÎŽãªã¬ã³ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1061]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âαâãã«ãã¬ããœãŒã«ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1062]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1063]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ä»£è¬ç£ç©åã³ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1062ã®é åãå«ãçµæç©ã
[æ¬çºæ1064]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ä»£è¬ç£ç©ãããã¯ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1062ã®é åãå«ãçµæç©ã
[æ¬çºæ1065]
åèšÎ±â2âÎŽãªã¬ã³ãã¯ãã¬ããã³ãã³ãããã¯ãã¬ã¬ããªã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ããéžæããããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1066]
åèšÎ±â2âÎŽãªã¬ã³ãé»å®³å€ã¯ãã¬ããã³ãã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1067]
åèšÎ±â2âÎŽãªã¬ã³ãé»å®³å€ã¯ããã¬ã¬ããªã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1068]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšÎ±â2âÎŽé»å®³å€ã¯ãæ²»çæå¹éã®ã¬ããã³ãã³ãããã¯ãã¬ã¬ããªã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®çµæç©ã
[æ¬çºæ1069]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ããã¹ãããã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšÎ±â2âÎŽé»å®³å€ã¯ãæ²»çæå¹éã®ã¬ããã³ãã³ãããã¯ãã¬ã¬ããªã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®çµæç©ã
[æ¬çºæ1070]
ãã«ãã¬ããœã³ãšÎ±â2âÎŽãªã¬ã³ãããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã1ïŒ30ã1ïŒ125éééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1068ã®çµæç©ã
[æ¬çºæ1071]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1072]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1073]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã25ïœïœã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1074]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããæ¬çºæ1068ã®çµæç©ã
[æ¬çºæ1075]
ååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããã1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1076]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1077]
åèšçµã¿åããã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1078]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1060ã®çµæç©ã
[æ¬çºæ1079]
ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããæ¹æ³ã§ãã£ãŠãæ¬çºæ1069ã®æ²»çæå¹éã®çµã¿åãããã該åºä¹³åç©ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1080]
ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯è©²ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã®ããã¹ãããšãã³ããªããŒãããã¯ãã®ã©ã»ãæ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«ããæ²»çæå¹éã®çµæç©ããåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¹æ³ã
[æ¬çºæ1081]
ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã®ããã¹ãããšãã³ããªããŒããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãäž»ã«å«ããæ²»çæå¹éã®çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1082]
æ²»çæå¹éã®ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ããå«ãçµæç©ãæäžããããšãå«ã¿ã該ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ãåã³6âαâãã«ãã¬ããœãŒã«ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããªãã³ã«ãã®ãããã©ãã°ãããã¯ä»£è¬ç£ç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1083]
æ²»çæå¹éã®ãã«ãã¬ããœã³ãããããœã³ããããã¯ãã«ã¡ãã§ã³ããŸãã¯ãã«ãã¬ããœã³ãããããœã³ããããã¯ãã«ã¡ãã§ã³ã®äž»ã«ããã¹ãããšãã³ããªããŒæ··åç©ããããã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1084]
æ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1085]
æ²»çæå¹éã®ããããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1086]
æ²»çæå¹éã®ãã«ã¡ãã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1087]
æ²»çæå¹éã®äž»ã«ããã¹ãããã«ãã¬ããœã³æ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1088]
æ²»çæå¹éã®äž»ã«ããã¹ããããããœã³æ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1089]
æ²»çæå¹éã®äž»ã«ããã¹ãããã«ã¡ãã§ã³æ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1090]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã®éã¯ãçŽ0ïŒ004ïœïœïŒïœïœããçŽ4ïŒ3ïœïœïŒïœïœãŸã§ã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ71ïœïœïŒïœïœãŸã§ãåã³æã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ21ïœïœïŒïœïœãŸã§å€åãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1091]
ãã«ãã¬ããœã³ã®éã¯ãçŽ0ïŒ004ïœïœïŒïœïœããçŽ4ïŒ3ïœïœïŒïœïœãŸã§ã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ71ïœïœïŒïœïœãŸã§ãåã³æã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ21ïœïœïŒïœïœãŸã§å€åãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1092]
ããã¹ãããã«ãã¬ããœã³ã®éã¯ãçŽ0ïŒ004ïœïœïŒïœïœããçŽ4ïŒ3ïœïœïŒïœïœãŸã§ã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ71ïœïœïŒïœïœãŸã§ãåã³æã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ21ïœïœïŒïœïœãŸã§å€åãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1093]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®ããçšéç¯å²ã¯ã1æ¥åœããçŽ0ïŒ25ïœïœã50ïœïœã奜ãŸããã¯1æ¥åœããçŽ0ïŒ25ïœïœã25ïœïœãæã奜ãŸããã¯1æ¥åœããçŽ0ïŒ25ïœïœã15ïœïœãšå€åãã該çšéã¯ãååæè¬åœ¢æ ã«è£œå€åããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1094]
åèšçµæç©ã¯ã50ïŒ ã60ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1095]
åèšçµæç©ã¯ã60ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1096]
åèšçµæç©ã¯ã70ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1097]
åèšçµæç©ã¯ã80ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1098]
åèšçµæç©ã¯ã90ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1099]
ååã®åºå®æè¬åœ¢æ ã¯ã1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1100]
æ²»çæå¹çšéã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æïŒïœïœïœïœïœïœïœïœïŒããŸãã¯èäžã®çµè·¯ãä»ããŠãå šèº«æäžããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1101]
åèšçµæç©ã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1102]
åèšå»è¬çµæç©ã¯ãç¥çµé害æ§çŒçãèéšçãæ ¢æ§çŒçãç³å°¿ç æ§ç¥çµé害æ§çŒçãäžåç¥çµçãå¹»è¢çãè€åæ§å±æçŒççå矀ã®çã¿ã垯ç¶ç±ç¹åŸçãçŒç±çãç¹çºæ§çŒçãççæ§çŒçãçæ§çŒçãè¡åŸçŒçãç·ç¶ççãé çãçé çãã¢ããã£ãã¢çŒçãå€é°éšçãé質æ§èè±ççŒçãéææ§è žçå矀ïŒïŒ©ïŒ¢ïŒ³ïŒãé¢ç¯ççŒçãåã³è ±çãæ²»çãããäºé²ãããåã³ãããããå埩ãããããã«äœ¿çšããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1103]
åèšå»è¬çµæç©ã¯ãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãæ²»çãããäºé²ãããåã³ããããå埩ãããããã«äœ¿çšããããæ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1001]
çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1002]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1003]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããã®ãããã©ãã°ããŸãã¯ãã®ããããã®ä»»æã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1004]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããããã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1003ã®é åãå«ãçµæç©ã
[æ¬çºæ1005]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1003ã®é åãå«ãçµæç©ã
[æ¬çºæ1006]
åèšçŽæ¥äœååα2ã¢ãã¬ããªã³äœåè¬ã¯ãã¢ãã©ã¯ãããžã³ãããªã¢ããžã³ãã¯ãããžã³ãããããžã³ããã¯ã¹ã¡ããããžã³ãã°ã¢ããã³ãºãã°ã¢ã³ãã¡ã·ã³ãããã§ãã·ãžã³ãã¡ããããžã³ããããã£ãžã³ããã¶ããžã³ãããããžã³ããã·ã©ãžã³ãåã³ãã¡ãã«ããžã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1007]
åèšçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ã¯ãã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1008]
åèšçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ã¯ãæç¶æŸåºæ§è£œå€äžã®ã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®é åãå«ãçµæç©ã
[æ¬çºæ1009]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšçŽæ¥äœååαâ2ã¢ãã¬ããªã³äœåè¬ã¯ãæ²»çæå¹éã®ã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1010]
ãã«ãã¬ããœã³ãšã¯ãããžã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã90ïŒ1ã22ïŒ5ïŒ1éééšã®ãªãŒããŒã®çžä¹çãªçµã¿åããç¯å²ã«å¯Ÿå¿ãããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1009ã®çµæç©ã
[æ¬çºæ1011]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããã¯ãããžã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ã1æ¥åœããçŽ0ïŒ00018ïœïœïŒïœïœã0ïŒ0086ïœïœïŒïœïœã§ãããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1012]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããã¯ãããžã³ã®ããçšéç¯å²ã¯ã0ïŒ0125ïœïœã0ïŒ6ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1013]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããã¯ãããžã³ã®ããçšéç¯å²ã¯ã0ïŒ0125ïœïœã0ïŒ3ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1014]
1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1015]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1016]
åèšçµã¿åããã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1010ã®çµæç©ã
[æ¬çºæ1017]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1018]
èéšçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1019]
ç¥çµé害æ§çŒçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1020]
çé çã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1021]
äžåç¥çµçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1022]
å€é°éšçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1023]
éææ§è žçå矀ã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1024]
垯ç¶ç±ç¹åŸç¥çµçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1025]
ç³å°¿ç æ§ç¥çµé害ã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1026]
ã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçã§ããçã¿ãæ²»çããããã®ãæ¬çºæ1001ã®çµæç©ã
[æ¬çºæ1027]
çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1028]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1027ã®é åãå«ãçµæç©ã
[æ¬çºæ1029]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1027ã®é åãå«ãçµæç©ã
[æ¬çºæ1030]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1029ã®é åãå«ãçµæç©ã
[æ¬çºæ1031]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1029ã®é åãå«ãçµæç©ã
[æ¬çºæ1032]
ã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã第2ã®ååç©ã§ãããæ¬çºæ1027ã®é åãå«ãçµæç©ã
[æ¬çºæ1033]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã¯ãæ²»çæå¹éã§ãããæ¬çºæ1027ã®çµæç©ã
[æ¬çºæ1034]
ãã«ãã¬ããœã³ãšã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã3ïŒ200éééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1027ã®çµæç©ã
[æ¬çºæ1035]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ã1æ¥åœããçŽ5ïœïœïŒïœïœã57ïœïœïŒïœïœã§ãããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1036]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã®ããçšéç¯å²ã¯ã325ïœïœã4000ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1037]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã®ããçšéç¯å²ã¯ã325ïœïœã4000ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1038]
1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1039]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1040]
ãã«ãã¬ããœã³åã³ã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1034ã®çµæç©ã
[æ¬çºæ1041]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1027ã®çµæç©ã
[æ¬çºæ1042]
ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçã䟵害å容æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãççãå€åœ¢æ§é¢ç¯çãé¢ç¯ãªãŠããã也ç¬æ§é¢ç¯çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããæ¹æ³ã§ãã£ãŠãæ¬çºæ1034ã®æ²»çæå¹éã®çµã¿åãããã該åºä¹³åç©ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1043]
çžä¹çæ¯çã®ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1044]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1045]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1046]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1045ã®é åãå«ãçµæç©ã
[æ¬çºæ1047]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1045ã®é åãå«ãçµæç©ã
[æ¬çºæ1048]
åèšã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ã¯ãã¢ã¹ããªã³ããžãã«ããµã«ããµã«ãµã¬ãŒããã€ããããã§ã³ããã¯ã¹ã€ããããã§ã³ãããããã»ã³ããã§ããããã§ã³ãã±ããããã§ã³ããã¯ã¹ã±ããããã§ã³ããã«ã«ããããã§ã³ããªããµãããžã³ããããœãããã§ã³ãã€ã³ãã¡ã¿ã·ã³ããã«ã¡ãã³ãã¹ãªã³ãã¯ããšããã©ã¯ãã±ããã©ã¯ããžã¯ããã§ãã¯ïŒïœïœïœïœïœïœ ïœïœïœïŒãããã¡ãã³ããããã·ã«ã ãã¡ããã·ã«ã ããããã·ã«ã ããããã·ã«ã ããã«ããã·ã«ã ãã€ãœãã·ã«ã ãã¡ãã§ãã é žãã¡ã¯ããã§ãã é žããã«ãã§ãã é žããã«ãã§ãã é žãã»ã¬ã³ãã·ããããã§ã³ãã·ãããã«ãã³ãã·ãããã¬ã³ãã·ããã«ãã©ã³ãã·ãããšããªã³ãã·ãããã£ãã³ãã·ããã¹ã«ãã³ã¢ããªãããã¡ã¹ãªãããªã³ãã§ãã³ããªãžã³ãã¯ãããã·ã³é žãããã«ãã©ãªã³ããŽãããã°ãµãã«ã«ã·ããªãªãŒã«ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1049]
åèšã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ã¯ãã€ããããã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1043ã®é åãå«ãçµæç©ã
[æ¬çºæ1050]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé»å®³å€ã¯ãæ²»çæå¹éã®ã€ããããã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1043ã®çµæç©ã
[æ¬çºæ1051]
ãã«ãã¬ããœã³ãšã€ããããã§ã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã1ïŒ90éééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1052]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããã€ããããã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ã1æ¥åœããçŽ3ïœïœïŒïœïœã35ïœïœïŒïœïœã§ãããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1053]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããã€ããããã§ã³ã®ããçšéç¯å²ã¯ã200ïœïœã2400ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1054]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããã€ããããã§ã³ã®ããçšéç¯å²ã¯ã200ïœïœã2400ïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1055]
1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1056]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1057]
åèšçµã¿åããã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1050ã®çµæç©ã
[æ¬çºæ1058]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1043ã®çµæç©ã
[æ¬çºæ1059]
ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçã䟵害å容æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããæ¹æ³ã§ãã£ãŠãæ¬çºæ1050ã®æ²»çæå¹éã®çµã¿åãããã該åºä¹³åç©ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1060]
çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒÎ±â2âÎŽãªã¬ã³ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
[æ¬çºæ1061]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âαâãã«ãã¬ããœãŒã«ã6âβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1062]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1063]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ä»£è¬ç£ç©åã³ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1062ã®é åãå«ãçµæç©ã
[æ¬çºæ1064]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ä»£è¬ç£ç©ãããã¯ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1062ã®é åãå«ãçµæç©ã
[æ¬çºæ1065]
åèšÎ±â2âÎŽãªã¬ã³ãã¯ãã¬ããã³ãã³ãããã¯ãã¬ã¬ããªã³ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ããéžæããããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1066]
åèšÎ±â2âÎŽãªã¬ã³ãé»å®³å€ã¯ãã¬ããã³ãã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1067]
åèšÎ±â2âÎŽãªã¬ã³ãé»å®³å€ã¯ããã¬ã¬ããªã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®é åãå«ãçµæç©ã
[æ¬çºæ1068]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšÎ±â2âÎŽé»å®³å€ã¯ãæ²»çæå¹éã®ã¬ããã³ãã³ãããã¯ãã¬ã¬ããªã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®çµæç©ã
[æ¬çºæ1069]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ããã¹ãããã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšÎ±â2âÎŽé»å®³å€ã¯ãæ²»çæå¹éã®ã¬ããã³ãã³ãããã¯ãã¬ã¬ããªã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããæ¬çºæ1060ã®çµæç©ã
[æ¬çºæ1070]
ãã«ãã¬ããœã³ãšÎ±â2âÎŽãªã¬ã³ãããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã1ïŒ30ã1ïŒ125éééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããæ¬çºæ1068ã®çµæç©ã
[æ¬çºæ1071]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽ0ïŒ004ïœïœïŒïœïœã0ïŒ71ïœïœïŒïœïœã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1072]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã50ïœïœã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1073]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã25ïœïœã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1074]
ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ã1æ¥åœãã0ïŒ25ïœïœã15ïœïœã§ãããæ¬çºæ1068ã®çµæç©ã
[æ¬çºæ1075]
ååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããã1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1076]
æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1077]
åèšçµã¿åããã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããæ¬çºæ1069ã®çµæç©ã
[æ¬çºæ1078]
çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãæ¬çºæ1060ã®çµæç©ã
[æ¬çºæ1079]
ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããæ¹æ³ã§ãã£ãŠãæ¬çºæ1069ã®æ²»çæå¹éã®çµã¿åãããã該åºä¹³åç©ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1080]
ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãããŸãã¯è©²ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã®ããã¹ãããšãã³ããªããŒãããã¯ãã®ã©ã»ãæ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«ããæ²»çæå¹éã®çµæç©ããåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¹æ³ã
[æ¬çºæ1081]
ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã®ããã¹ãããšãã³ããªããŒããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãäž»ã«å«ããæ²»çæå¹éã®çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1082]
æ²»çæå¹éã®ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ããå«ãçµæç©ãæäžããããšãå«ã¿ã該ãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ã6âβâãã«ãã¬ããœãŒã«ãåã³6âαâãã«ãã¬ããœãŒã«ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããªãã³ã«ãã®ãããã©ãã°ãããã¯ä»£è¬ç£ç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1083]
æ²»çæå¹éã®ãã«ãã¬ããœã³ãããããœã³ããããã¯ãã«ã¡ãã§ã³ããŸãã¯ãã«ãã¬ããœã³ãããããœã³ããããã¯ãã«ã¡ãã§ã³ã®äž»ã«ããã¹ãããšãã³ããªããŒæ··åç©ããããã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1084]
æ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1085]
æ²»çæå¹éã®ããããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1086]
æ²»çæå¹éã®ãã«ã¡ãã§ã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1087]
æ²»çæå¹éã®äž»ã«ããã¹ãããã«ãã¬ããœã³æ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1088]
æ²»çæå¹éã®äž»ã«ããã¹ããããããœã³æ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1089]
æ²»çæå¹éã®äž»ã«ããã¹ãããã«ã¡ãã§ã³æ··åç©ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãå«æããå»è¬çµæç©ããåèšåºä¹³åç©ã«æäžããããšãå«ãã該åºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1090]
åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²4ã¢ã³ã¿ãŽãã¹ãã®éã¯ãçŽ0ïŒ004ïœïœïŒïœïœããçŽ4ïŒ3ïœïœïŒïœïœãŸã§ã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ71ïœïœïŒïœïœãŸã§ãåã³æã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ21ïœïœïŒïœïœãŸã§å€åãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1091]
ãã«ãã¬ããœã³ã®éã¯ãçŽ0ïŒ004ïœïœïŒïœïœããçŽ4ïŒ3ïœïœïŒïœïœãŸã§ã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ71ïœïœïŒïœïœãŸã§ãåã³æã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ21ïœïœïŒïœïœãŸã§å€åãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1092]
ããã¹ãããã«ãã¬ããœã³ã®éã¯ãçŽ0ïŒ004ïœïœïŒïœïœããçŽ4ïŒ3ïœïœïŒïœïœãŸã§ã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ71ïœïœïŒïœïœãŸã§ãåã³æã奜ãŸããã¯çŽ0ïŒ004ïœïœïŒïœïœããçŽ0ïŒ21ïœïœïŒïœïœãŸã§å€åãããçã¿ã®æ²»çã®ããã®æ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1093]
ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®ããçšéç¯å²ã¯ã1æ¥åœããçŽ0ïŒ25ïœïœã50ïœïœã奜ãŸããã¯1æ¥åœããçŽ0ïŒ25ïœïœã25ïœïœãæã奜ãŸããã¯1æ¥åœããçŽ0ïŒ25ïœïœã15ïœïœãšå€åãã該çšéã¯ãååæè¬åœ¢æ ã«è£œå€åããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1094]
åèšçµæç©ã¯ã50ïŒ ã60ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1095]
åèšçµæç©ã¯ã60ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1096]
åèšçµæç©ã¯ã70ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1097]
åèšçµæç©ã¯ã80ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1098]
åèšçµæç©ã¯ã90ïŒ ãè¶ ããããã¹ãããšãã³ããªããŒãå«ããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1099]
ååã®åºå®æè¬åœ¢æ ã¯ã1æ¥ãéããŠ1åã2åã3åããŸãã¯4åæäžããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1100]
æ²»çæå¹çšéã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æïŒïœïœïœïœïœïœïœïœïŒããŸãã¯èäžã®çµè·¯ãä»ããŠãå šèº«æäžããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1101]
åèšçµæç©ã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1102]
åèšå»è¬çµæç©ã¯ãç¥çµé害æ§çŒçãèéšçãæ ¢æ§çŒçãç³å°¿ç æ§ç¥çµé害æ§çŒçãäžåç¥çµçãå¹»è¢çãè€åæ§å±æçŒççå矀ã®çã¿ã垯ç¶ç±ç¹åŸçãçŒç±çãç¹çºæ§çŒçãççæ§çŒçãçæ§çŒçãè¡åŸçŒçãç·ç¶ççãé çãçé çãã¢ããã£ãã¢çŒçãå€é°éšçãé質æ§èè±ççŒçãéææ§è žçå矀ïŒïŒ©ïŒ¢ïŒ³ïŒãé¢ç¯ççŒçãåã³è ±çãæ²»çãããäºé²ãããåã³ãããããå埩ãããããã«äœ¿çšããããçã¿ã®æ²»çã®ããã®æ¬çºæ1080ã®æ¹æ³ã
[æ¬çºæ1103]
åèšå»è¬çµæç©ã¯ãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãæ²»çãããäºé²ãããåã³ããããå埩ãããããã«äœ¿çšããããæ¬çºæ1080ã®æ¹æ³ã
Claims (16)
- çžä¹çæ¯çã®ïŒïœïŒãªããªã€ãïŒïŒŽïŒ¬ïŒ²ïŒã¢ã³ã¿ãŽãã¹ãããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãïŒïœïŒã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãšãå«ããåºä¹³åç©ã«ãããçã¿ã®æ²»çã®ããã®çµæç©ã
- åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²ïŒã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããã«ããã«ãã«ãã£ãã³ããã«ã¡ãã§ã³ãããããœã³ãããã«ãã£ã³ãã¡ãã«ãã«ãã¬ããœã³ããµããã«ãã¡ã³ãã·ãããžã ããã«ããªã³ããŒã«ãã¢ã¡ã³ããã©ãã³ããã«ããªãã³ããã«ããã«ãã«ãã£ãã³ãïŒâβâãã«ãã¬ããœãŒã«ããã®ä»£è¬ç£ç©åã³ãããã©ãã°ïŒå šãŠã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ãå«ãïŒããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ãããªã矀ããéžæããããè«æ±é ïŒã«èšèŒã®é åãå«ãçµæç©ã
- åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²ïŒã¢ã³ã¿ãŽãã¹ãã¯ããã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããè«æ±é ïŒã«èšèŒã®é åãå«ãçµæç©ã
- åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²ïŒã¢ã³ã¿ãŽãã¹ãã¯ãæç¶æŸåºæ§è£œå€äžã®ãã«ãã¬ããœã³ããªãã³ã«ãã®ãããã©ãã°ããŸãã¯ãã®ä»»æã®ãšãã³ããªããŒåã³ãšãããŒåœ¢æ ãªãã³ã«ãã®é©åãªæ··åç©ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããè«æ±é ïŒã«èšèŒã®é åãå«ãçµæç©ã
- åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²ïŒã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒïŒâãã«ãã¬ããœã³ïŒããã¹ããâãã«ãã¬ããœã³ïŒãåã³ãã®é©åãªæ··åç©ãåã³ãã®ãããã©ãã°ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããè«æ±é ïŒã«èšèŒã®é åãå«ãçµæç©ã
- ã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ã第ïŒã®ååç©ã§ãããè«æ±é ïŒã«èšèŒã®é åãå«ãçµæç©ã
- åèšãªããªã€ãïŒïŒŽïŒ¬ïŒ²ïŒã¢ã³ã¿ãŽãã¹ãã¯ãæ²»çæå¹éã®ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã§ãããåèšã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã¯ãæ²»çæå¹éã§ãããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ãã«ãã¬ããœã³ãšã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®ããããã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã¯ãïŒïŒïŒïŒïŒéééšã®çžä¹çãªçµã¿åããã«å¯Ÿå¿ããééïŒééã®çµã¿åããç¯å²å ã§ãããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ãã«ãã¬ããœã³ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãçŽïŒïŒïŒïŒïŒïœïœïŒïœïœãïŒïŒïŒïŒïœïœïŒïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãããã¯æº¶åªåç©ã®çšéç¯å²ã¯ãïŒæ¥åœããçŽïŒïœïœïŒïœïœãïŒïŒïœïœïŒïœïœã§ãããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ãïŒæ¥åœããïŒïŒïŒïŒïœïœãïŒïŒïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã®ããçšéç¯å²ã¯ãïŒïŒïŒïœïœãïŒïŒïŒïŒïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ãã«ãã¬ããœã³ã®ããçšéç¯å²ã¯ãïŒæ¥åœããïŒïŒïŒïŒïœïœãïŒïŒïœïœã§ãããã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã®ããçšéç¯å²ã¯ãïŒïŒïŒïœïœãïŒïŒïŒïŒïœïœã§ãããåèšçµæç©ã¯ãååã®åºå®çµã¿åããæè¬åœ¢æ ã«è£œå€åããããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ïŒæ¥ãéããŠïŒåãïŒåãïŒåããŸãã¯ïŒåæäžããããè«æ±é ïŒã«èšèŒã®çµæç©ã
- æ²»çæå¹çšéã®å»è¬çµæç©ã¯ãç²èãçµéŒ»ãçµå£ãéçµå£ãèè žãå±æããŸãã¯èäžçµè·¯ãå«ãããããã«éå®ãããªãçµè·¯ãä»ããŠãå šèº«æäžããããè«æ±é ïŒã«èšèŒã®çµæç©ã
- ãã«ãã¬ããœã³åã³ã¢ã»ãã«âãã©âã¢ãããã§ããŒã«ã¯ãååæè¬åœ¢æ ã§ããã該ååæè¬åœ¢æ ã¯ãé å€ãããŒã³ãžããããŒããããŒããã£ã³ãã£ã液äœãç²æ«ãã¹ãã¬ãŒãã¯ãªãŒã ãè»èãåã³åå€ã®åœ¢æ ã§ãããè«æ±é ïŒã«èšèŒã®çµæç©ã
- çã¿ãæ²»çãããäºé²ãããåã³çã¿ããå埩ãããããã®ãè«æ±é ïŒã«èšèŒã®çµæç©ã
- ãã®å¿ èŠãããåºä¹³åç©ã«ãããŠãç¥çµé害æ§çŒçã䟵害å容æ§çŒçãã¢ããã£ãã¢èŠçŽ ã䌎ã䟵害å容æ§çŒçãçé çãççãå€åœ¢æ§é¢ç¯çãé¢ç¯ãªãŠããã也ç¬æ§é¢ç¯çãäžåç¥çµçãå€é°éšçãéææ§è žçå矀ã垯ç¶ç±ç¹åŸç¥çµçããŸãã¯ç³å°¿ç æ§ç¥çµé害ãæ²»çããããã®ãè«æ±é ïŒã«èšèŒã®çµæç©ã
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/799,287 | 2013-03-13 | ||
US13/799,287 US20130310412A1 (en) | 2010-06-28 | 2013-03-13 | Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain |
US13/841,100 US9205081B2 (en) | 2010-04-29 | 2013-03-15 | Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain |
US13/837,099 US9095548B2 (en) | 2010-04-29 | 2013-03-15 | Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain |
US13/837,099 | 2013-03-15 | ||
US13/841,100 | 2013-03-15 | ||
US13/851,773 US20150111917A9 (en) | 2010-04-29 | 2013-03-27 | Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain |
US13/851,773 | 2013-03-27 | ||
US13/851,267 US20150111916A9 (en) | 2010-04-29 | 2013-03-27 | Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof |
US13/851,267 | 2013-03-27 | ||
PCT/US2014/025771 WO2014160077A1 (en) | 2013-03-13 | 2014-03-13 | Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016512561A JP2016512561A (ja) | 2016-04-28 |
JP2016512561A5 true JP2016512561A5 (ja) | 2017-04-13 |
Family
ID=51625328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501961A Pending JP2016512561A (ja) | 2013-03-13 | 2014-03-13 | ãªããªã€ãïŒããŒã«æ§å容äœïŒã¢ã³ã¿ãŽãã¹ãããã®ããã¹ãããšãã³ããªããŒãå«ããçã¿ã軜æžããããã®çµæç©ãåã³ãã®ããã®äœ¿çšæ¹æ³ |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2968293A4 (ja) |
JP (1) | JP2016512561A (ja) |
AU (1) | AU2014244152A1 (ja) |
CA (1) | CA2942641A1 (ja) |
WO (1) | WO2014160077A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016105449A1 (en) * | 2014-12-22 | 2016-06-30 | Seth Lederman | Compounds for use as pain therapeutics |
JP2018530749A (ja) * | 2015-08-31 | 2018-10-18 | ãªãŒãžã§ã³ã ãªã 㶠ãŠãããŒã·ã㣠ãªã ãããœã¿ | ãªããªã€ãå容äœèª¿ç¯å ååã³ãã®äœ¿çš |
EP3511320A4 (en) * | 2016-09-09 | 2020-04-15 | Takeda Pharmaceutical Company Limited | CYCLIC COMPOUND |
US20180147201A1 (en) | 2016-10-31 | 2018-05-31 | Allodynic Therapeutics, Llc | Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
CA2314893C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
US20040192715A1 (en) * | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
JP2006131545A (ja) * | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | ç¥çµå æ§çŒçæ²»çå€ |
GB2447014A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
EP2240022B1 (en) * | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
US8202525B2 (en) * | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
US20110269727A1 (en) * | 2010-04-29 | 2011-11-03 | Toledano Annette C | Composition to reduce allodynic back pain and related method of use |
US20130189354A1 (en) * | 2010-10-07 | 2013-07-25 | Trinity Laboratories, Inc., | Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy |
-
2014
- 2014-03-13 WO PCT/US2014/025771 patent/WO2014160077A1/en active Application Filing
- 2014-03-13 EP EP14773349.7A patent/EP2968293A4/en not_active Ceased
- 2014-03-13 CA CA2942641A patent/CA2942641A1/en not_active Abandoned
- 2014-03-13 AU AU2014244152A patent/AU2014244152A1/en not_active Abandoned
- 2014-03-13 JP JP2016501961A patent/JP2016512561A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016512561A5 (ja) | ||
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
AR061967A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metil-piridin-3-il-amino)-5-metil-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos | |
IL194885A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
CL2013001677A1 (es) | Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia. | |
CL2007002375A1 (es) | Compuestos derivados de heteroarilo, inhibidores de citocina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, inflamacion, artritis, psoriasis, diabetes, | |
CL2008000835A1 (es) | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm | |
WO2007095091A3 (en) | Oral delivery of therapeutic agents using tight junction agonists | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
MA41256B1 (fr) | Dosage spécifique de site d'un inhibiteur de btk | |
RU2016115093A (ru) | ЀаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑОÑ, ÑПЎеÑжаÑÐ°Ñ Ð°ÐœÑагПМОÑÑ trpa1 О аМалÑгеÑОÑеÑкОй Ð°Ð³ÐµÐœÑ | |
BR112017027688A2 (pt) | Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados | |
US20160158222A1 (en) | Combinations of opioid/tlr4 antagonist and a cyclooxygenase (cox) inhibitor for use in the treatment of pain | |
IL300130A (en) | New combinations for antigen-based therapy | |
JP2014532728A5 (ja) | ||
AR090126A1 (es) | Composicion de doxilamina y piridoxina y/o sus metabolitos o sales | |
JP2013517304A5 (ja) | ||
UY33061A (es) | Composiciones para comprimidos desintegrables oralmente de ondansetrón para prevenir náuseas y vómitos | |
PE20120956A1 (es) | Composicion farmaceutica que contiene buprenorfina y nalmefeno | |
US20150111916A9 (en) | Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof | |
JP2016520556A5 (ja) | ||
CN107405359A (zh) | å å«çŸæŽæ康çè¯ç©ç»åç© | |
WO2012022120A8 (zh) | äºæ°¢å¡åç±»ååç© |